Almac Diagnostics Sees Benefit for Test Pipeline in New Ovarian, Breast Cancer Studies | GenomeWeb

This story was originally posted on June 3.

By Justin Petrone

Almac Diagnostics believes that two recent studies could aid its plans to develop new tests for cancer.

In the studies — both of which were presented at the American Society of Clinical Oncology's annual meeting in Chicago last week — Almac researchers and academic collaborators used the company's Disease Specific Arrays to identify biomarkers associated with ovarian and breast cancer.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: researchers explore the transfer of host genetic material into viruses, and more.

It's too difficult to correct or retract a flawed scientific paper, researchers write in Nature.

A proposed bill would require NSF to only fund research that's in "the national interest."

Australia's Commonwealth Scientific and Industrial Research Organisation plans to eliminate up to 350 jobs.